Raising revenue guidance typically signals to investors that a company is performing well and expects stronger financial results than previously anticipated. For Corcept Therapeutics, increasing their FY24 revenue guidance above analyst estimates suggests confidence in their growth trajectory and operational performance. This positive adjustment is likely to be viewed favorably by investors, potentially leading to an increase in stock price in the short term as market sentiment around the company improves.